Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria.

Biotechnology

Pharmaceutical

Prokaryotics

Keith Bostian

Holly Sutterlin

Terry Roemer

David Perlin

Brian Burr

Pamela Demain

Sang Ho Lee

Sherman Tim Waddell

The Scientific Advisory Team at Prokaryotics, composed of experienced founders and directors in chemistry, microbiology, and operations, provides strategic guidance on optimizing Merck's early-stage antibiotic programs. Their expertise helps shape the development, manufacturing, and commercialization efforts for novel therapies targeting both Gram-negative and Gram-positive bacteria.

Scientific Advisory Team

Scientific Advisory Board

Leadership Team

Scientific Advisory Team

About

Team members

Other teams at Prokaryotics

Scientific Advisory Board

Leadership Team